Byron Hewett appointed as new SomaLogic CEO

Byron Hewett appointed as new SomaLogic CEO


The Board of Directors of SomaLogic Inc. (a privately held biotechnology company) announced today that Byron Hewett has been appointed as Chief Executive Officer (CEO), effective Dec 2, 2013. SomaLogic was founded in 2000 by its original  CEO, Larry Gold, who will continue as Chairman of the Board. Dr. Gold will also continue to work full time at SomaLogic, advising the new CEO and other senior management leaders.

“Our first decade at SomaLogic was dedicated to building an innovative new class of aptamers, creating an opportunity for new therapeutics and a transformational proteomics technology, and we have been hugely successful in doing that,” said Dr. Gold. “Now, to reach our commercial goals and our ultimate mission of transforming healthcare, it was clear to me that we needed additional leadership with the deep business experience and knowledge to take SomaLogic to the next level. I believe that Byron Hewett is exactly the leader we need at this critical stage of our company’s growth, and we are very fortunate to have found him, and to have him agree to join us here in Boulder.”

“I am excited to join SomaLogic’s impressive team to help expand  adoption of their stunning technology across the health care continuum,” said Mr. Hewett. “The opportunity to make a significant difference in the lives of people around the world is a rare one, and I believe that what SomaLogic has developed under Larry’s leadership promises to do just that. I am grateful to the Board and to Larry for putting their trust in me to help achieve this mission, which is at the heart of SomaLogic.”

Byron Hewett has 25+ years of commercial experience, almost entirely in the area of diagnostics. Most recently, he served as Chairman and CEO of BioBehavioral Diagnostics (BioBDx), a company offering the first FDA-cleared objective test for ADHD using proprietary technology. BioBDx was acquired by NCS Pearson in August 2013 as a key component to execute their strategy in ADHD.

Prior to his work with BioBDx, Mr. Hewett was President and CEO of Immunicon, an oncology diagnostics company, where he had previously held the position of Chief Operating Officer and General Manager, cancer products. He has also served as SVP of Sales and Marketing and General Manager, North America for Qiagen, Inc., and held leadership positions at Abbott Diagnostics, Chiron/Bayer, and BioCircuits.